Compare KMDA & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMDA | FTH |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.3M | 507.8M |
| IPO Year | 2013 | 2021 |
| Metric | KMDA | FTH |
|---|---|---|
| Price | $8.15 | $9.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | $13.75 | ★ $56.15 |
| AVG Volume (30 Days) | 103.5K | ★ 691.0K |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | ★ 6.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | $13.63 | N/A |
| P/E Ratio | $24.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.60 | $8.58 |
| 52 Week High | $9.35 | $42.14 |
| Indicator | KMDA | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 24.63 |
| Support Level | $7.99 | N/A |
| Resistance Level | $8.62 | $21.97 |
| Average True Range (ATR) | 0.25 | 1.92 |
| MACD | 0.09 | -0.64 |
| Stochastic Oscillator | 88.61 | 3.21 |
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.